Executive Interviews

1. State Of The Orphan Space 3/1/2024

   Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.

2. NORD Expands Advocacy And Support For Rare Disease Patients, And Industry 2/29/2024

   NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.

3. No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease 2/16/2024

   Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.

4. Executive Outlook: Converting Innovative Science Into Predictable Returns 12/1/2023

   Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

5. Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place 12/1/2023

   Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

6. An Outsourcing Future Of Information Sharing And Commercial Streamlining 12/1/2023

   Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.

7. Defining A Competitive Next-Gen RNA Therapeutic In 2024 12/1/2023

   To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.

8. Accelerating Drug Development With Real World Data 12/1/2023

   Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.

9. Finance And Funding: Anticipating Improvement, Planning For Uncertainty 12/1/2023

   Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

10. Biopharma's Eminent Challenges In 2024 — Inside & Out 12/1/2023

    A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.